Cannabis is renowned for its production of a wide range of bioactive compounds, most notably tetrahydrocannabinol (THC) and cannabidiol (CBD). Yet, the evolutionary origins of these molecules have long been a mystery—until recently. New research is shedding light on how these compounds evolved and how they could be harnessed for future medical use.

Unraveling the Evolution of Cannabinoids

Researchers at Wageningen University & Research (WUR) in the Netherlands have traced how cannabis developed the ability to produce THC, CBD, and another important cannabinoid, cannabichromene (CBC). Their discoveries not only clarify the plant’s evolutionary path but also point to new ways to take advantage of its chemical diversity.

Modern cannabis strains show significant variation in the levels of cannabinoids like THC, CBD, and CBC. These differences are mainly due to the action of specific synthase enzymes, which have evolved over millions of years. The enzymes present in today’s cannabis are highly specialized and quite different from those found in the plant’s ancient relatives.

Recreating Ancient Enzymes

Using a method called ancestral sequence reconstruction, the scientists recreated ancient cannabinoid-producing enzymes using modern genetic data. By expressing these enzymes in the lab, the team could observe which cannabinoids they generated and compare their functions to those of current enzymes.

The study found that, unlike today’s specialized enzymes, ancient versions were more versatile. They could produce several cannabinoids—including THC, CBD, and CBC—from a single precursor molecule.

“What once appeared to be evolutionarily ‘unfinished’ is actually highly valuable,” said WUR researcher Robin van Velzen, who co-led the study with Cloé Villard. “These ancestral enzymes are more robust and adaptable than their modern counterparts, making them promising for new biotechnological and pharmaceutical uses.”

Exploring the Promise of CBC

One of the most fascinating findings relates to CBC. While THC and CBD have dominated cannabis research, CBC is emerging as a potentially important but largely overlooked cannabinoid. Most modern cannabis plants contain less than 1% CBC, making it difficult to study and produce in large amounts.

“Currently, there is no cannabis plant that naturally produces high levels of CBC,” van Velzen noted. “Introducing this enzyme into cannabis could lead to innovative medicinal strains.”

Early studies indicate that CBC may have anti-inflammatory, anticonvulsant, and antibacterial effects, though its therapeutic potential is not as well understood as that of THC or CBD.

Implications for Biotechnology and Medicine

The team also found that these reconstructed ancestral enzymes are easier to produce in microorganisms like yeast than their modern counterparts. This could allow for more efficient production of cannabinoids—including rare ones—without relying on traditional plant cultivation, a breakthrough for both research and pharmaceutical manufacturing.

By engineering hybrid enzymes based on these ancient forms, the researchers pinpointed key amino acid changes that shaped the evolution of cannabinoid-producing enzymes. These hybrid and ancestral enzymes not only displayed unique activities but were also more suitable for laboratory production.

In summary, this research deepens our understanding of how cannabinoids are synthesized and where they come from. It paves the way for new approaches in breeding, biotechnology, and the creation of innovative medicinal cannabis products.